Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists reveal how natural antibiotic kills tuberculosis bacterium

17.09.2012
A natural product secreted by a soil bacterium shows promise as a new drug to treat tuberculosis report scientists in a new study published in EMBO Molecular Medicine.
A team of scientists working in Switzerland has shown how pyridomycin, a natural antibiotic produced by the bacterium Dactylosporangium fulvum, works. This promising drug candidate is active against many of the drug-resistant types of the tuberculosis bacterium that no longer respond to treatment with the front-line drug isoniazid.

“Nature and evolution have equipped some bacteria with potent defense mechanisms to protect them against other bugs that share their habitat. Screening natural products generated by these organisms is therefore a powerful way to find possible new drugs to fight infectious diseases,” said Stewart Cole, lead author of the study, EMBO Member and a professor at the École Polytechnique Fédérale de Lausanne (EPFL), Switzerland. “Using this approach we have shown that nature’s antibiotic pyridomycin is a very selective killer of Mycobacterium tuberculosis, the bacterium responsible for tuberculosis in humans. It is also active against mycobacteria that have developed resistance to front-line drug treatments such as isoniazid.”

Tuberculosis causes up to two million deaths annually. There is a significant need for new drugs since the effectiveness of current antibiotics is compromised by the increasing prevalence of drug-resistant tuberculosis. The most effective drugs used to treat tuberculosis, for example isoniazid and rifampicin, are often no longer effective.

The researchers identified a protein, the enzyme NADH-dependent enoyl(acyl carrier protein) reductase or InhA, which is the principal target for the antibiotic. “By selecting and isolating M. tuberculosis mutants resistant to pyridomycin and sequencing their genome we have found that a single gene named inhA is responsible for resistance to this natural product,” added Cole.

The gene inhA is needed to produce the InhA protein, which is already known as a target for tuberculosis drug isoniazid. It turns out that pyridomycin can bind to the same pocket on the InhA enzyme as isoniazid but at a different site and in a way that involves a different sequence of molecular events. It is these differences that give pyridomycin the ability to overcome drug-resistant strains of mycobacteria.

The scientists showed that in live bacteria treatment with pyridomycin leads to the depletion of mycolic acids, fatty acids that are an essential component of the bacterial cell wall.

“Our finding that pyridomycin kills Mycobacterium tuberculosis by inhibiting InhA, even in clinically isolated bacteria that are resistant to the drug isoniazid, provides a great opportunity to develop pyridomycin or a related agent for the treatment of drug-resistant tuberculosis,” remarked Cole.

Towards a new tuberculosis drug: Pyridomycin – Nature’s isoniazid

Ruben C Hartkoorn, Claudia Sala, João Neres, Florence Pojer, Sophie J. Magnet, Raju Mukherjee, Swapna Uplekar, Stefanie Boy-Röttger, Karl-Heinz Altmann, Stewart T. Cole

Read the paper:
http://onlinelibrary.wiley.com/doi/10.1002/emmm.201201689/abstract
doi: 10.1002/emmm.201201689
Read more about Dr. Cole’s research:
http://actu.epfl.ch/news/old-news-is-good-news-for-tb-drug-discovery/
Further information on EMBO Molecular Medicine is available at www.embomolmed.org

Media Contacts
Barry Whyte
Head | Public Relations and Communications

Yvonne Kaul
Communications Offer
Tel: +49 6221 8891 108/111
communications@embo.org

About EMBO
EMBO stands for excellence in the life sciences. The organization enables the best science by supporting talented researchers, stimulating scientific exchange and advancing policies for a world-class European research environment.

EMBO is an organization of 1500 leading life scientist members that fosters new generations of researchers to produce world-class scientific results. EMBO helps young scientists to advance their research, promote their international reputations and ensure their mobility. Courses, workshops, conferences and scientific journals disseminate the latest research and offer training in cutting-edge techniques to maintain high standards of excellence in research practice. EMBO helps to shape science and research policy by seeking input and feedback from our community and by following closely the trends in science in Europe.

Yvonne Kaul | EMBO
Further information:
http://www.embo.org
http://www.embo.org/news-a-media-centre/press-releases/research-news.html

More articles from Life Sciences:

nachricht Microscope measures muscle weakness
16.11.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

nachricht Good preparation is half the digestion
16.11.2018 | Max-Planck-Institut für Stoffwechselforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Purdue cancer identity technology makes it easier to find a tumor's 'address'

16.11.2018 | Health and Medicine

Good preparation is half the digestion

16.11.2018 | Life Sciences

Microscope measures muscle weakness

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>